Fmr Llc - Oct 18, 2023 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role: Other*, 10%+ Owner
Signature: Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol: GPCR
Transactions as of: Oct 18, 2023
Transactions value $: -$1,145,681
Form type: 4
Date filed: 10/23/2023, 03:55 PM
Previous filing: Oct 12, 2023
Next filing: Nov 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	GPCR	Ordinary Shares						45.1K	Oct 18, 2023	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
holding	GPCR	Ordinary Shares						531K	Oct 18, 2023	F-Prime Capital Partners Life Sciences Fund VI LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	GPCR	American Depositary Shares	Sale	-$89.8K	-1.37K	-25.01%	$65.64	4.1K	Oct 18, 2023	Ordinary Shares	4.1K	F-Prime Capital Partners Life Sciences Advisors Fund VI LP	F1, F2
transaction	GPCR	American Depositary Shares	Sale	-$1.06M	-16.1K	-25%	$65.64	48.3K	Oct 18, 2023	Ordinary Shares	48.3K	F-Prime Capital Partners Life Sciences Fund VI LP	F1, F2
holding	GPCR	American Depositary Shares						1.59M	Oct 18, 2023	Ordinary Shares	4.77M	Shares held by persons and entities whose shares are subject to reporting by the undersigned	F1
holding	GPCR	American Depositary Shares						41	Oct 18, 2023	Ordinary Shares	123	FIMM, LLC	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.
F2	The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC.